Rapafusyn Pharmaceuticals Raises $28M in Funding to Advance Drug Development
Rapafusyn Pharmaceuticals Raises $28M in Series A Funding
(Linkedin), a research services company based in the United States, recently secured $28M in Series A funding to advance their innovative approach to drug discovery and development. They specialize in utilizing macrocyclic peptide-based non-degrading molecular glues (RapaGlues™) to target challenging therapeutic areas.
Funding Amount: $28 million
Industry: Research Services
Employee Count: 11-50
CEO: Sean X. Hu (CEO Linkedin)
What Rapafusyn Pharmaceuticals needs to buy: Rapafusyn Pharmaceuticals is seeking partnerships with pharmaceutical companies, biotech and research institutions, and investors in biotechnology. They are looking for collaborations in drug discovery and development using non-degrading molecular glues, as well as manufacturing and supply chain solutions, and regulatory and compliance services to support their innovative therapeutic drug development efforts.